Lipopolysaccharide-binding protein: a possible diagnostic marker for Gram-negative bacteremia in neutropenic cancer patients
Claudi S. M. Oude Nijhuis(University Medical Center Groningen), Eveline S.J.M. de Bont(Hôpital Saint-Michel), Jourik A. Gietema(University Medical Center Groningen), Edo Vellenga(University Medical Center Groningen), Winette T.A. van der Graaf(The Netherlands Cancer Institute), Harry J.M. Groen(University Medical Center Groningen), Willem A. Kamps(Pediatric Oncology Group), Simon Daenen
Cited by 51
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
|The Lancet|1998|964
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
|The Lancet Oncology|2009|932
Evidence Based Selection of Housekeeping Genes
|PLoS ONE|2007|772